title: Infectious Disease. How to bolster the antifungal pipeline.
authors: The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. The National Aspergillosis Centre, University Hospital of South Manchester, Manchester, UK. ddenning@manchester.ac.
authors: David W
authors: DW
authors: Denning
authors: The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. The Manchester Fungal Infection Group, The University of Manchester, Manchester, UK.
authors: Michael J
authors: MJ
authors: Bromley
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000401:mortality*; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D001249:Asthma / Q000382:microbiology; D003550:Cystic Fibrosis / Q000382:microbiology; D015195:Drug Design; D025141:Drug Resistance, Fungal / Q000235:genetics; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000382:microbiology; D065819:Voriconazole / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000935:Antifungal Agents; D065819:Voriconazole